Aloe Therapeutics is developing a first-in-class platform immunotherapy for solid tumors, called Allo-Immunotherapy (AIM-001). AIM-001 is a localized, nontraditional cell-based immunotherapy implanted at the tumor site during biopsy or tumor removal surgery. AIM-001 acts as “bait” for the immune system by triggering the powerful transplant rejection immune response to trigger an influx of activated immune cells at the tumor site. An activated immune system and “hot” tumor, full of activated immune cells, increases effectiveness of common cancer therapies, like checkpoint immunotherapy. Turn cold tumors hot and hot tumors hotter for patients with difficult-to-treat solid tumors and limited therapeutic options
External link for Aloe Therapeutics
Germantown, MD, US
No one asks the hard questions like teenagers. Looking forward to hearing their perspective and questions about Allo-Immunotherapy.
This is happening! Join us live stream to hear tough kids from the Bronx ask tough questions about the science and the promise of biomedical innovations for #fightingcancer. Next up is the amazing Martha Sklavos PhD, PMP from Aloe Therapeutics. #musicbeatscancer